Quidel Corporation has received the CE Mark for the Quidel® Molecular hMPV Real-Time RT-PCR Assay. This assay is Quidel's second molecular diagnostic test to receive authorization to market in Europe. This announcement follows the notice of the European launch of Quidel's first molecular diagnostic test -- its RT-PCR test for Influenza A+B on August 5th. Quidel's rapidly expanding menu of molecular diagnostic RT-PCR tests will provide several important benefits to the customer, including enhanced ease of use, reduced processing time, and ready-to-use reagent configurations.

The CE Mark for Quidel's molecular hMPV assay clears the way for the launch of another infectious disease molecular test offering in Europe well in advance of the respiratory disease season.

This product is not for sale in the U.S. at this time.

'With the completion of each assay development project, we become even more confident in our ability to execute our pipeline strategy,' said Douglas Bryant, president and chief executive officer of Quidel Corporation. 'The CE Mark for hMPV is another milestone met, and evidence that we are on track with our molecular diagnostic strategy.'